Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics)
Clinical trials sponsored by Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics), explained in plain language.
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New targeted pill shows promise for tough lung cancer
Disease control Recruiting nowThis early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC